Biomarker Pancreatic Cancer Study
Pancreatic cancer is the third leading cause of cancer-related deaths in the U.S. and is usually diagnosed in advanced stages. Currently, there is no screening test, and the disease is difficult to diagnose.
The Biomarker Pancreatic Cancer Study at HonorHealth Research Institute offers the opportunity to participate in an international study supported in part by the National Institute of Health (NIH) in developing new ways to detect pancreatic cancer. The HonorHealth Research Institute is also part of the Pancreatic Cancer Detection Consortium (PCDC), a group of researchers and clinicians that collaborate to improve the detection of pancreatic cancers.
Under the leadership of Erkut Borazanci, MD, MS, medical oncologist, clinical investigator, HonorHealth Research Institute, the goal of this study is to develop a biomarker by using the latest technology that may help us identify pancreatic cancer earlier. A biomarker is a tool used to determine the presence of disease.
Assessments and consultations may include:
- Family history assessment
- Visit with a physician or nurse practitioner
- Genetic counseling and testing
- MRI
- Blood samples
- Endoscopy
Referral criteria
If an individual 18 years or older has one or more of the following, they may be eligible to participate in the Biomarker Pancreatic Cancer Study:
- Two or more relatives with a pancreatic cancer diagnosis
- One must be a parent, sibling or child
- A genetic mutation that may increase the risk of developing pancreatic cancer
- A diagnosis of pancreatic cancer or cyst